Get the Stockscreener App
58.23
2.28%
-1.36
Pre-market:
58.45
0.22
+0.38%
Belite Bio Inc Adr stock is traded at $58.23, with a volume of 22,496.
It is down -2.28% in the last 24 hours and down -9.72% over the past month.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
See More
Previous Close:
$59.59
Open:
$59.6
24h Volume:
22,496
Relative Volume:
0.57
Market Cap:
$1.77B
Revenue:
-
Net Income/Loss:
$-32.61M
P/E Ratio:
-49.59
EPS:
-1.1742
Net Cash Flow:
-
1W Performance:
+3.24%
1M Performance:
-9.72%
6M Performance:
-12.96%
1Y Performance:
+53.24%
1-Day Range:
$57.70
$59.60
1-Week Range:
$53.59
$60.04
52-Week Range:
$38.11
$86.53
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
58.23 | 1.77B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Maxim Group | Buy |
| Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-23 | Initiated | SVB Securities | Outperform |
| Aug-01-22 | Initiated | H.C. Wainwright | Buy |
| Jul-01-22 | Initiated | The Benchmark Company | Buy |
Belite Bio Inc Adr Stock (BLTE) Latest News
Brokers Offer Predictions for Belite Bio FY2028 Earnings - Defense World
Belite Bio shareholders approve all resolutions at AGM By Investing.com - Investing.com South Africa
Belite Bio Announces Key Resolutions from 2025 General Meeting - TipRanks
Belite Bio shareholders approve all resolutions at AGM - Investing.com
Stargardt Disease Market Predicted to See Upsurge Through 2034, - openPR.com
Belite Bio, Inc. Appoints New Auditor - TipRanks
Benchmark Reiterates Buy Rating for Belite Bio (NASDAQ:BLTE) - Defense World
Belite Bio stock target raised to $80 at Benchmark By Investing.com - Investing.com South Africa
Belite Bio price target raised to $80 from $79 at Benchmark - TipRanks
Belite Bio stock target raised to $80 at Benchmark - Investing.com
Belite Bio, Inc. ADR: Promising Clinical Progress and Strong Financial Position Drive Buy Rating - TipRanks
Cantor Fitzgerald Expects Reduced Earnings for Belite Bio - The AM Reporter
Cantor Fitzgerald Forecasts Weaker Earnings for Belite Bio - Defense World
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Up 17.1% in February - Defense World
HC Wainwright Has Pessimistic View of Belite Bio Q1 Earnings - Defense World
Belite Bio (NASDAQ:BLTE) Receives Buy Rating from HC Wainwright - Defense World
Belite Bio’s (BLTE) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Belite Bio’s Earnings Call: Cautious Optimism Amid Progress - TipRanks
Belite Bio Announces 2025 Annual Shareholder Meeting - TipRanks
Belite Bio stock holds $100 target post-results By Investing.com - Investing.com India
Belite Bio stock holds $100 target post-results - Investing.com
Positive Buy Rating for Belite Bio, Inc. Driven by Promising Phase 3 DRAGON Trial Results and Regulatory Prospects - TipRanks
Belite Bio (NASDAQ:BLTE) Shares Gap Down After Earnings Miss - Defense World
Belite Bio Advances in Retinal Disease Trials and Financial Position - TipRanks
Earnings call transcript: Belite Bio ADR Q4 2024 sees steady R&D progress - Investing.com Australia
Belite Bio reports Q4 EPS (32c), consensus (31c) - TipRanks
Belite Bio Reports 2024 Financial Results and Clinical Progress - TipRanks
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website - Markets Insider
Belite Bio Releases 2024 Annual Report on Website - TipRanks
Belite Bio Reports Positive Interim Analysis Results for Phase 3 DRAGON Trial and Financial Update for Q4 2024 - Nasdaq
Public market insider buying at Savaria (SIS) - The Globe and Mail
Belite Bio's $145M War Chest Powers Critical Phase 3 Eye Disease Trial - StockTitan
Just Released: Belite Bio 2024 Annual Report Reveals Full Year Performance - Stock Titan
Belite Bio (NASDAQ:BLTE) Trading Down 1.6% – Time to Sell? - Defense World
Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics - The Globe and Mail
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 ... - The Bakersfield Californian
Biotech Pioneer Belite Bio Unveils Q4 and 2024 Performance: Key Retinal Disease Updates Coming March 17 - Stock Titan
Is Meta Platforms Stock a Buy, Sell, or Hold Ahead of Llama 4 Launch? - The Globe and Mail
Parkland Reports Fourth Quarter and Year-End 2024 Results; Initiates Review of Strategic Alternatives - The Globe and Mail
Darwin CX Expands Internationally, Aiming to Tackle Global Publishing Challenges with Locally Tailored Solutions - The Globe and Mail
Can Belite Bio's Retinal Disease Treatments Impress Investors at Upcoming Leerink Conference? - StockTitan
Belite Bio to Participate in the Leerink Partners Global Healthcare Conference - The Globe and Mail
2 Large-Cap Stocks with Exciting Potential and 1 to Avoid - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Shares Gap UpShould You Buy? - MarketBeat
Promising Phase 3 Results for Belite Bio’s Tinlarebant in Stargardt Disease Boost Buy Rating - TipRanks
Belite Bio’s Phase 3 Trial for Stargardt Disease Drug Advances - TipRanks
Can Belite Bio's Tinlarebant Become First Treatment for Stargardt Disease? Phase 3 Data Shows Promise - Stock Titan
Belite Bio Announces Interim Analysis Results from the - GlobeNewswire
Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading Volume – Still a Buy? - The AM Reporter
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 9.2% in January - MarketBeat
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):